3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
41
Radiotherapy
38
Cisplatin
35
Oxaliplatin
32
Leucovorin
24
Paclitaxel
22
Irinotecan
20
Docetaxel
17
Neoadjuvant Therapy
14
Carboplatin
13
Radiation
12
Capecitabine
12
Surgical Procedures, Operative
10
Cetuximab
8
Biopsy
8
durvalumab
7
Gefitinib
7
Chemotherapy, Adjuvant
7
tremelimumab
6
pembrolizumab
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Folfox protocol
6
Taxes
5
Immunohistochemistry
5
Endoscopy
5
Gene Expression Profiling
4
Epirubicin
4
Drug Therapy
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma Of Esophagus
×
monalizumab
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn